Search This Blog

Thursday, April 5, 2018

Nilotinib


 NILOTINIB
Nilotinib is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML). Chronic myelogenous leukemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein.



Nilotinib 
Reference
Tripathi K.D.,” Essentials of Medical Pharmacology”, Jaypee Brothers Medical Publishers (P) LTD, New Delhi, Seventh Edition, Pg No. 870

at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

 

  • sulfasalazine-Mechanism of action
    Mechanism of action of sulfasalazine:- The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfa...
  • DOXACURIUM
    Doxacurium   binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in...
  • NIFEDIPINE
    NIFEDIPINE: MECHANISM OF ACTION- •    It’s a prototype DHP with a rapid onset of action with short duration. •    It’s a calcium channel...